Cargando…

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib

Proteasomal inhibition revolutionized myeloma therapies in this decade of novel agents. The only US Food and Drug Administration approved proteasome inhibitor so far, bortezomib effectively targets the constitutive proteasome subunit β5 of the 26S proteasome. Bortezomib induces high and quality resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Nooka, Ajay, Gleason, Charise, Casbourne, Daniela, Lonial, Sagar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563316/
https://www.ncbi.nlm.nih.gov/pubmed/23386784
http://dx.doi.org/10.2147/BTT.S24580

Ejemplares similares